Answers are grounded in this paper and cite their sources.
Psychotropic drug-induced weight change is clinically important but remains difficult to compare across large numbers of medications. We analysed 222,545 deduplicated user-generated reviews covering 176 psychotropic medications and acetaminophen as a negative control. A fine-tuned classifier identified reviews describing weight gain, weight loss, or no change, and a Qwen3-8B language model extracted quantified weight changes in kilograms. We derived a Net Weight Effect (NWE), defined as the proportion of reviews describing weight gain minus the proportion describing weight loss (range −1 to +1), and the mean weight change in kilograms, both with bootstrap 95% confidence intervals. Antipsychotics had the highest class-level weight liability (NWE + 0.154; mean +12.6 kg), whereas stimulants showed the most weight-reducing profile (NWE − 0.050; mean −7.1 kg). Olanzapine, mirtazapine, and risperidone ranked highest for weight gain, whereas bupropion/naltrexone and topiramate ranked lowest. Long-term use (>6 months) was associated with a larger mean gain than medium-term use (+8.8 kg vs +2.3 kg), and females reported weight gain more frequently than males. Per-drug rankings were highly concordant across the four source platforms (Kendall’s W = 0.83). In an exploratory receptor-affinity analysis, alpha-2 adrenergic affinity was the strongest correlate of NWE (rho = 0.594; permutation FDR p = 0.006), whereas H1 histamine affinity was the strongest correlate of mean weight change (rho = 0.638; permutation FDR p = 0.042). Large-scale AI-assisted analysis of patient narratives can therefore generate clinically useful real-world rankings of psychotropic weight liability while also highlighting mechanistically plausible, though correlational, pharmacological associations.
No takes yet. Share an insight, caveat, or question.
Natter et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: